Risk‐adapted treatment in multiple myeloma: Does more make it merrier?
Kaiser et al. offer management recommendations for transplant‐eligible, high‐risk multiple myeloma (HRMM), derived from recent trials exploring treatment intensification in the various phases of front‐line therapy. The definition of HRMM continues to evolve with emergence of novel genomic insights a...
Saved in:
| Published in | British journal of haematology Vol. 205; no. 3; pp. 767 - 769 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Blackwell Publishing Ltd
01.09.2024
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Kaiser et al. offer management recommendations for transplant‐eligible, high‐risk multiple myeloma (HRMM), derived from recent trials exploring treatment intensification in the various phases of front‐line therapy. The definition of HRMM continues to evolve with emergence of novel genomic insights and impact of modern therapies, underscoring the need to expand beyond traditional interphase fluorescence in situ hybridization cytogenetics and International Staging System staging for a precise risk assessment. Despite progress, ongoing challenges in treatment delivery and tolerability underscore the urgency for exploring novel approaches like T‐cell redirecting bispecific antibodies and chimeric antigen receptor T‐cell to enhance outcomes in this complex patient population.
Commentary on: Kaiser et al. Diagnosis and initial treatment of transplant‐eligible high‐risk myeloma patients: A British Society for Haematology/UK Myeloma Society Good Practice Paper. Br J Haematol 2024; 205:833‐839. |
|---|---|
| AbstractList | Kaiser et al. offer management recommendations for transplant‐eligible, high‐risk multiple myeloma (HRMM), derived from recent trials exploring treatment intensification in the various phases of front‐line therapy. The definition of HRMM continues to evolve with emergence of novel genomic insights and impact of modern therapies, underscoring the need to expand beyond traditional interphase fluorescence in situ hybridization cytogenetics and International Staging System staging for a precise risk assessment. Despite progress, ongoing challenges in treatment delivery and tolerability underscore the urgency for exploring novel approaches like T‐cell redirecting bispecific antibodies and chimeric antigen receptor T‐cell to enhance outcomes in this complex patient population.
Commentary on: Kaiser et al. Diagnosis and initial treatment of transplant‐eligible high‐risk myeloma patients: A British Society for Haematology/UK Myeloma Society Good Practice Paper. Br J Haematol 2024; 205:833‐839. Kaiser et al. offer management recommendations for transplant-eligible, high-risk multiple myeloma (HRMM), derived from recent trials exploring treatment intensification in the various phases of front-line therapy. The definition of HRMM continues to evolve with emergence of novel genomic insights and impact of modern therapies, underscoring the need to expand beyond traditional interphase fluorescence in situ hybridization cytogenetics and International Staging System staging for a precise risk assessment. Despite progress, ongoing challenges in treatment delivery and tolerability underscore the urgency for exploring novel approaches like T-cell redirecting bispecific antibodies and chimeric antigen receptor T-cell to enhance outcomes in this complex patient population. Commentary on: Kaiser et al. Diagnosis and initial treatment of transplant-eligible high-risk myeloma patients: A British Society for Haematology/UK Myeloma Society Good Practice Paper. Br J Haematol 2024; 205:833-839.Kaiser et al. offer management recommendations for transplant-eligible, high-risk multiple myeloma (HRMM), derived from recent trials exploring treatment intensification in the various phases of front-line therapy. The definition of HRMM continues to evolve with emergence of novel genomic insights and impact of modern therapies, underscoring the need to expand beyond traditional interphase fluorescence in situ hybridization cytogenetics and International Staging System staging for a precise risk assessment. Despite progress, ongoing challenges in treatment delivery and tolerability underscore the urgency for exploring novel approaches like T-cell redirecting bispecific antibodies and chimeric antigen receptor T-cell to enhance outcomes in this complex patient population. Commentary on: Kaiser et al. Diagnosis and initial treatment of transplant-eligible high-risk myeloma patients: A British Society for Haematology/UK Myeloma Society Good Practice Paper. Br J Haematol 2024; 205:833-839. Kaiser et al. offer management recommendations for transplant‐eligible, high‐risk multiple myeloma (HRMM), derived from recent trials exploring treatment intensification in the various phases of front‐line therapy. The definition of HRMM continues to evolve with emergence of novel genomic insights and impact of modern therapies, underscoring the need to expand beyond traditional interphase fluorescence in situ hybridization cytogenetics and International Staging System staging for a precise risk assessment. Despite progress, ongoing challenges in treatment delivery and tolerability underscore the urgency for exploring novel approaches like T‐cell redirecting bispecific antibodies and chimeric antigen receptor T‐cell to enhance outcomes in this complex patient population.Commentary on: Kaiser et al. Diagnosis and initial treatment of transplant‐eligible high‐risk myeloma patients: A British Society for Haematology/UK Myeloma Society Good Practice Paper. Br J Haematol 2024; 205:833‐839. Kaiser et al. offer management recommendations for transplant-eligible, high-risk multiple myeloma (HRMM), derived from recent trials exploring treatment intensification in the various phases of front-line therapy. The definition of HRMM continues to evolve with emergence of novel genomic insights and impact of modern therapies, underscoring the need to expand beyond traditional interphase fluorescence in situ hybridization cytogenetics and International Staging System staging for a precise risk assessment. Despite progress, ongoing challenges in treatment delivery and tolerability underscore the urgency for exploring novel approaches like T-cell redirecting bispecific antibodies and chimeric antigen receptor T-cell to enhance outcomes in this complex patient population. Commentary on: Kaiser et al. Diagnosis and initial treatment of transplant-eligible high-risk myeloma patients: A British Society for Haematology/UK Myeloma Society Good Practice Paper. Br J Haematol 2024; 205:833-839. |
| Author | Zanwar, Saurabh Sborov, Douglas W. Galarza Fortuna, Gliceida M. |
| Author_xml | – sequence: 1 givenname: Saurabh orcidid: 0000-0001-5074-8453 surname: Zanwar fullname: Zanwar, Saurabh organization: Mayo Clinic – sequence: 2 givenname: Gliceida M. surname: Galarza Fortuna fullname: Galarza Fortuna, Gliceida M. organization: University of Utah – sequence: 3 givenname: Douglas W. orcidid: 0000-0003-4268-2698 surname: Sborov fullname: Sborov, Douglas W. email: douglas.sborov@hci.utah.edu organization: University of Utah |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39072706$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kM1KxDAQgIMouqsefAEpeNFDdydJ02a9iK4_qwiC6DmkzSx2t2nXpEX25iP4jD6J0VUPgnMZGD4-hq9P1uumRkL2KAxomGE-exrQUZqla6RHeSpiRhO6TnoAkMUUErlF-t7PACgHQTfJFh9BxjJIe2RyX_r5--ubNnrRoolah7q1WLdRWUe2q9pyUWFkl1g1Vh9H5w36yDYunPQco7KNLDpXojvZIRtTXXnc_d7b5PHy4mE8iW_vrq7Hp7dxwTKZxlPDtUlEno8wxUQw4Cw1AqdMY0GZKYBnNBdSIAitE6CGmjwJz0rJDIDO-TY5XHkXrnnu0LfKlr7AqtI1Np1XHKRI5UiKJKAHf9BZ07k6fKc4Db2YkFwE6mhFFa7x3uFULVxptVsqCuozrwp51VfewO5_G7vcovklf3oGYLgCXsoKl_-b1NnNZKX8AN-ghSQ |
| Cites_doi | 10.1200/JOP.19.00639 10.1056/NEJMoa2400712 10.1200/JCO.23.01277 10.1182/blood-2023-174044 10.1016/S2352-3026(23)00236-3 10.1016/S2352-3026(20)30354-9 10.1038/s41591-024-03050-2 10.1056/NEJMoa2312054 10.1016/S1470-2045(23)00405-9 10.1111/bjh.19623 10.1200/JCO.19.02515 10.1200/JCO.22.02567 10.1200/JCO.23.01696 10.1200/JCO.21.02614 |
| ContentType | Journal Article |
| Copyright | 2024 The Author(s). published by British Society for Haematology and John Wiley & Sons Ltd. 2024 The Author(s). British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd. 2024. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: 2024 The Author(s). published by British Society for Haematology and John Wiley & Sons Ltd. – notice: 2024 The Author(s). British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd. – notice: 2024. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | 24P WIN CGR CUY CVF ECM EIF NPM AAYXX CITATION 7T5 H94 7X8 |
| DOI | 10.1111/bjh.19676 |
| DatabaseName | Open Access: Wiley-Blackwell Open Access Journals Wiley Free Archive Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Immunology Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef AIDS and Cancer Research Abstracts Immunology Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic AIDS and Cancer Research Abstracts MEDLINE CrossRef |
| Database_xml | – sequence: 1 dbid: 24P name: Open Access: Wiley-Blackwell Open Access Journals url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1365-2141 |
| EndPage | 769 |
| ExternalDocumentID | 10_1111_bjh_19676 39072706 BJH19676 |
| Genre | commentary Journal Article Review |
| GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1KJ 1OB 1OC 23N 24P 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 6J9 6P2 702 7PT 8-0 8-1 8-3 8-4 8-5 8F7 8UM 930 A01 A03 AAESR AAEVG AAHHS AAKAS AANLZ AAONW AASGY AAXRX AAYEP AAZKR ABCQN ABCUV ABEML ABJNI ABLJU ABOCM ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZCM ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFNX AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AHEFC AI. AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS EGARE EJD EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IH2 IHE IX1 J0M J5H K48 KBYEO L7B LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N4W N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PALCI Q.N Q11 QB0 R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ TEORI UB1 V8K V9Y VH1 W8V W99 WBKPD WHWMO WIH WIJ WIK WIN WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR X7M XG1 YFH YOC YUY ZGI ZXP ZZTAW ~IA ~WT CGR CUY CVF ECM EIF NPM AAYXX CITATION 7T5 H94 7X8 |
| ID | FETCH-LOGICAL-c2786-fd3ad45bb9e6e4520326d5ef2aec12dc0371b585e05aa401d1db4072882d00ab3 |
| IEDL.DBID | DR2 |
| ISSN | 0007-1048 1365-2141 |
| IngestDate | Thu Oct 24 17:09:59 EDT 2024 Wed Oct 23 13:12:37 EDT 2024 Wed Oct 30 12:31:57 EDT 2024 Tue Oct 29 09:30:38 EDT 2024 Thu Oct 24 09:52:39 EDT 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | phase 3 high‐risk multiple myeloma HRMM |
| Language | English |
| License | Attribution-NonCommercial 2024 The Author(s). British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c2786-fd3ad45bb9e6e4520326d5ef2aec12dc0371b585e05aa401d1db4072882d00ab3 |
| Notes | Saurabh Zanwar and Gliceida M. Galarza Fortuna contributed equally to the manuscript. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| ORCID | 0000-0003-4268-2698 0000-0001-5074-8453 |
| OpenAccessLink | https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fbjh.19676 |
| PMID | 39072706 |
| PQID | 3119625835 |
| PQPubID | 36395 |
| PageCount | 3 |
| ParticipantIDs | proquest_miscellaneous_3085689854 proquest_journals_3119625835 crossref_primary_10_1111_bjh_19676 pubmed_primary_39072706 wiley_primary_10_1111_bjh_19676_BJH19676 |
| PublicationCentury | 2000 |
| PublicationDate | September 2024 |
| PublicationDateYYYYMMDD | 2024-09-01 |
| PublicationDate_xml | – month: 09 year: 2024 text: September 2024 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: Oxford |
| PublicationTitle | British journal of haematology |
| PublicationTitleAlternate | Br J Haematol |
| PublicationYear | 2024 |
| Publisher | Blackwell Publishing Ltd |
| Publisher_xml | – name: Blackwell Publishing Ltd |
| References | 2020; 38 2020; 16 2023; 10 2021; 8 2024; 42 2023; 41 2023; 24 2023; 390 2024 2023; 142 2022; 40 e_1_2_2_4_1 e_1_2_2_14_1 e_1_2_2_5_1 e_1_2_2_13_1 e_1_2_2_6_1 e_1_2_2_12_1 e_1_2_2_7_1 e_1_2_2_11_1 e_1_2_2_10_1 e_1_2_2_2_1 e_1_2_2_3_1 e_1_2_2_9_1 e_1_2_2_8_1 e_1_2_2_15_1 |
| References_xml | – volume: 10 start-page: e890 issue: 11 year: 2023 end-page: e901 article-title: Minimal residual disease response‐adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single‐arm, phase 2 trial publication-title: Lancet Haematol – volume: 40 start-page: 3406 issue: 29 year: 2022 end-page: 3418 article-title: Second revision of the International Staging System (R2‐ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project publication-title: J Clin Oncol – year: 2024 article-title: Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant‐ineligible multiple myeloma: the randomized phase 3 BENEFIT trial publication-title: Nat Med – volume: 142 start-page: 207 issue: Suppl 1 year: 2023 article-title: Daratumumab, carfilzomib, lenalidomide, and dexamethasone induction and consolidation with tandem transplant in high‐risk newly diagnosed myeloma patients: final results of the phase 2 study IFM 2018‐04 publication-title: Blood – volume: 24 start-page: 1119 issue: 10 year: 2023 end-page: 1133 article-title: Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide‐based therapy (EMN12/HOVON‐129): final analysis of a non‐randomised, multicentre, phase 2 study publication-title: Lancet Oncol – year: 2024 article-title: Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma publication-title: N Engl J Med – volume: 42 start-page: 26 issue: 1 year: 2024 end-page: 37 article-title: Isatuximab, carfilzomib, lenalidomide, and dexamethasone for the treatment of high‐risk newly diagnosed multiple myeloma publication-title: J Clin Oncol – volume: 16 start-page: e1169 issue: 10 year: 2020 end-page: e1180 article-title: Variability in cytogenetic testing for multiple myeloma: a comprehensive analysis from across the United States publication-title: JCO Oncol Pract – volume: 8 start-page: e45 issue: 1 year: 2021 end-page: e54 article-title: Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high‐risk multiple myeloma (SWOG‐1211): primary analysis of a randomised, phase 2 trial publication-title: Lancet Haematol – volume: 38 start-page: 1928 issue: 17 year: 2020 end-page: 1937 article-title: Long‐term follow‐up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk‐adapted maintenance approach in newly diagnosed multiple myeloma publication-title: J Clin Oncol – year: 2024 article-title: Diagnosis and initial treatment of transplant‐eligible high‐risk myeloma patients: a British Society for Haematology/UK Myeloma Society Good Practice Paper publication-title: Br J Haematol – volume: 390 start-page: 301 issue: 4 year: 2023 end-page: 313 article-title: Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma publication-title: N Engl J Med – volume: 41 start-page: 3945 issue: 23 year: 2023 end-page: 3955 article-title: Daratumumab, cyclophosphamide, Bortezomib, Lenalidomide, and dexamethasone as induction and extended consolidation improves outcome in ultra‐high‐risk multiple myeloma publication-title: J Clin Oncol – volume: 42 start-page: 1229 issue: 11 year: 2024 end-page: 1240 article-title: Genomic classification and individualized prognosis in multiple myeloma publication-title: J Clin Oncol – ident: e_1_2_2_9_1 doi: 10.1200/JOP.19.00639 – ident: e_1_2_2_4_1 doi: 10.1056/NEJMoa2400712 – ident: e_1_2_2_8_1 doi: 10.1200/JCO.23.01277 – ident: e_1_2_2_13_1 doi: 10.1182/blood-2023-174044 – ident: e_1_2_2_10_1 doi: 10.1016/S2352-3026(23)00236-3 – ident: e_1_2_2_15_1 doi: 10.1016/S2352-3026(20)30354-9 – ident: e_1_2_2_5_1 doi: 10.1038/s41591-024-03050-2 – ident: e_1_2_2_3_1 doi: 10.1056/NEJMoa2312054 – ident: e_1_2_2_14_1 doi: 10.1016/S1470-2045(23)00405-9 – ident: e_1_2_2_2_1 doi: 10.1111/bjh.19623 – ident: e_1_2_2_7_1 doi: 10.1200/JCO.19.02515 – ident: e_1_2_2_11_1 doi: 10.1200/JCO.22.02567 – ident: e_1_2_2_12_1 doi: 10.1200/JCO.23.01696 – ident: e_1_2_2_6_1 doi: 10.1200/JCO.21.02614 |
| SSID | ssj0013051 |
| Score | 2.4985642 |
| SecondaryResourceType | review_article |
| Snippet | Kaiser et al. offer management recommendations for transplant‐eligible, high‐risk multiple myeloma (HRMM), derived from recent trials exploring treatment... Kaiser et al. offer management recommendations for transplant-eligible, high-risk multiple myeloma (HRMM), derived from recent trials exploring treatment... Kaiser et al. offer management recommendations for transplant‐eligible, high‐risk multiple myeloma (HRMM), derived from recent trials exploring treatment... Kaiser et al. offer management recommendations for transplant-eligible, high-risk multiple myeloma (HRMM), derived from recent trials exploring treatment... |
| SourceID | proquest crossref pubmed wiley |
| SourceType | Aggregation Database Index Database Publisher |
| StartPage | 767 |
| SubjectTerms | Bispecific antibodies Chimeric antigen receptors Clinical trials Cytogenetics Fluorescence in situ hybridization high‐risk multiple myeloma HRMM Humans Multiple myeloma Multiple Myeloma - diagnosis Multiple Myeloma - therapy phase 3 Risk Assessment |
| Title | Risk‐adapted treatment in multiple myeloma: Does more make it merrier? |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fbjh.19676 https://www.ncbi.nlm.nih.gov/pubmed/39072706 https://www.proquest.com/docview/3119625835 https://www.proquest.com/docview/3085689854 |
| Volume | 205 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JTsMwEB0BB8SFfSmUyiAOXFJlsbPAAbFVFRIIISr1gBTZsSNKaVrR9gAnPoFv5EsYZ4OCkBC3SHZixzNjv4lfngH2BJMejSg1VMxcg8qIG4JbzMClMeBx4JuRSNkWV26zRS_arD0Fh8W_MJk-RPnBTUdGOl_rAOdi-CXIxcN9Hd3H03LbluNpOtfZjf25g2Cy_LQ8D6ca6ueqQprFU945uRb9AJiTeDVdcBoLcFd0NeOZdOvjkahHL99UHP_5LoswnwNRcpx5zhJMqWQZZi_zrfYVaN50ht331zcu-QBRKSkZ6aSTkIKGSHrP6rHf4wfkrK-GRJN2SY93FemMSE9rPqqno1VoNc5vT5tGfuyCEdme7xqxdLikTIhAuYoyfcS6K5mKba4iy5aRFvkTmGUok3GO6Zm0pNAya4jVpWly4azBTNJP1AYQhHOIN3zq27FDBUWvjbnraskjz4wtEVVgtzBAOMjUNcIiK8ExCdMxqUC1ME2YB9gwdCwssxnixwrslMUYGnq_gyeqP8Y6CCddP_AZrcB6ZtKyFSfAHnsmPnw_NczvzYcnF830YvPvVbdgzkbwk3HRqjAzehqrbQQvI1GDaZte11Jf_QAM4upO |
| link.rule.ids | 315,783,787,1378,11576,27938,27939,46066,46308,46490,46732 |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JTuQwEC2xSAMXlmFrVs9oDlzSymI7CUJCLIPCekAgcUGRHTuiaTqN6O4DnPgEvpEvoZwNGIQ04hbJSey4quxn--UVwB_JlE8TSi2dMm5RlQhLCodZODWGIg0DO5E52-KURxf08JJdDsFm9S9MoQ9Rb7iZyMjHaxPgZkP6XZTLm-sm-o_Ph2EUw90z-Qv2zty3MwSblfnyfBxsaFDqChkeT_3ox9noE8T8iFjzKWd_Eq6qxhZMk3Zz0JfN5PEfHcfvfs0UTJRYlGwXzjMNQzr7CT9OytP2GYjOWr32y9OzUOIOgSmpSemklZGKiUg6D_q22xEbZK-re8TwdklHtDVp9UnHyD7q-61ZuNj_e74bWWXmBStx_YBbqfKEokzKUHNNmcmyzhXTqSt04rgqMTp_Ehca2mZC4ApNOUoapTWE68q2hfTmYCTrZnoBCCI6hBwBDdzUo5Ki46aCc6N65NupI5MG_K4sEN8VAhtxtTDBPonzPmnAcmWbuIyxXuw5WOYyhJAN-FUXY3SYIw-R6e4A70FEyYMwYLQB84VN61q8EFvs2_jy9dwyX1cf7xxG-cXi_9-6BmPR-clxfHxwerQE4y5ioYKatgwj_fuBXkEs05erucu-Aipj7ZE |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1LSwMxEB60gngR31arRvHgZWUfSXarB_FVan1QxIK3JdlksWq3xbYHb_4Ef6O_xMm-VETwtpDsBiYzmW92Jt8A7EqmfBpRaumYcYuqSFhSOMxC11gXcT2wI5lWW9zwZoe27tn9BBwWd2Eyfojyh5uxjPS8NgY-UPE3I5ePD_uoPj6fhClqYLihdabtrxSCzfJ2eT6eNTTIaYVMGU_56k9n9Ath_gSsqcdpzMFsDhXJcba38zChkwWYvs6T4YvQvO0Onz7e3oUSA8SNpKwZJ92EFIWCpPeqn_s9cUDO-npITFkt6YknTboj0jOsjPrlaAk6jfO706aVN0awItcPuBUrTyjKpKxrrikzTdC5Yjp2hY4cV0WGhk9iHKBtJgQGUMpR0hChIZpWti2ktwyVpJ_oVSAIuBARBDRwY49KinoVC84NKZFvx46MqrBTSCgcZPwXYRE3oBjDVIxVqBWyC3MTGIaeg2MuQ4RXhe1yGJXXZCREovtjnIOAjwf1gNEqrGQyL1fxMGx3fRs_vpduwt_LhyetZvqw9v-pWzDdPmuEVxc3l-sw4yJSyQrHalAZvYz1BiKNkdxMNeoT5BnMBA |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Risk%E2%80%90adapted+treatment+in+multiple+myeloma%3A+Does+more+make+it+merrier%3F&rft.jtitle=British+journal+of+haematology&rft.au=Zanwar%2C+Saurabh&rft.au=Gliceida+M+Galarza%C2%A0Fortuna&rft.au=Sborov%2C+Douglas+W&rft.date=2024-09-01&rft.pub=Blackwell+Publishing+Ltd&rft.issn=0007-1048&rft.eissn=1365-2141&rft.volume=205&rft.issue=3&rft.spage=767&rft.epage=769&rft_id=info:doi/10.1111%2Fbjh.19676&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-1048&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-1048&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-1048&client=summon |